Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The top 600 biopharma firms added $487 billion in market capitalisation in 2020, according to the Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review report,…
Inova and the Biotechnology Innovation Organization (BIO), in partnership with Evaluate announce the second annual series of Virtual Partnering events focused on critical…
COVID-19 will continue to be a defining issue for pharma and biotech companies in 2021, but overall the sector will start the year from a position of strength, according…
Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Evaluate…
Evaluate Ltd., the leading provider of commercial data to the life sciences industry, is pleased to announce the appointment of Martyn Hindley as Chief Financial Officer,…
Breakthrough offering combines the power of machine learning with the transparency of Evaluate’s renowned analytical approach for the most accurate analysis of drug…
The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019
“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.
Orphan drug sales reach $242bn by 2024, according to EvaluatePharma® Orphan Drug Report 2019
Evaluate Vantage releases annual analysis of Pharma, Biotech and Medtech performance
Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2019
Evaluate Ltd. releases annual “EvaluateMedtech World Preview 2018, Outlook to 2024” in conjunction with The Medtech Conference